Alvin Phan
YOU?
Author Swipe
View article: Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S4 – qPCR analysis results for CDC25A, E2F1, CDKN2B, CDC20, and MYC in MV4-11 cells treated with with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S1 – Flow Panels of Annexin and PI staining of U937 Cells following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S2 – FLT3 and CD99 surface level expression in primary blasts of sample USC001 and USC100.
View article: Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S3 – Western Blot data from USC100 following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S4 – qPCR analysis results for CDC25A, E2F1, CDKN2B, CDC20, and MYC in MV4-11 cells treated with with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S2 – FLT3 and CD99 surface level expression in primary blasts of sample USC001 and USC100.
View article: Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S3 – Western Blot data from USC100 following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S1 – Flow Panels of Annexin and PI staining of U937 Cells following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S3 – Western Blot data from USC100 following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure 3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Both antibody fusions exhibit binding and specificity in MV4-11 and U937 cells. A, CD99-A192 (Rhodamine) and FLT3-A192 (FITC) bound to MV4-11 AML cells (FLT3-ITD+/CD99+). B and C, In a competitive binding assay using U937 cells (FLT3−/CD99…
View article: Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S1 – Flow Panels of Annexin and PI staining of U937 Cells following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S4 – qPCR analysis results for CDC25A, E2F1, CDKN2B, CDC20, and MYC in MV4-11 cells treated with with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S4 – qPCR analysis results for CDC25A, E2F1, CDKN2B, CDC20, and MYC in MV4-11 cells treated with with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S2 – FLT3 and CD99 surface level expression in primary blasts of sample USC001 and USC100.
View article: Table 1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Table 1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Summary of expressed polypeptides
View article: Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S3 – Western Blot data from USC100 following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure 5 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 5 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Treatment with fusion protein formulations significantly reduced leukemia burden in NSG mice. A–C, 2 × 106 MV4-11 cells were engrafted IV into NSG mice. Mice were then treated with either A192, FLT3-A192, CD99-A192, or Co-Assembled at a do…
View article: Figure 7 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 7 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Signaling pathways and genes affected by the treatment with CD99/FLT3 fusion proteins. Following incubation of MV4-11 with treatments or controls, cell lysates were assessed using western blot against common signaling pathways associated w…
View article: Figure 4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Antibody nanoworms FLT3-A192 and CD99-A192 induce apoptosis and cell death. A–D, Trypan blue staining detects a decrease in cell viability across different cell lines FLT3-ITD+/CD99+ AML cells (MV4-11, MOLM-13), FLT3−/CD99+ cells (U937), a…
View article: Figure 2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Construction and biophysical characterization of an ELP fusion protein targeting both CD99 and FLT3 receptors. A, A single-chain variable fragment targeting either CD99 receptor or FLT3 receptor was genetically fused to the amino-terminus …
View article: Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S1 – Flow Panels of Annexin and PI staining of U937 Cells following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S2 – FLT3 and CD99 surface level expression in primary blasts of sample USC001 and USC100.
View article: Figure 1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Interplay between CD99 and FLT3 in FLT3-ITD AML. Flow cytometry was used to evaluate the surface level expression of FLT3 and CD99. A and B, Compared to naive MV4-11 cells, midostaurin-resistant (MV4-11-R) cells have a significant increase…
View article: Figure 6 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 6 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Midostaurin-resistant MV4-11 cells show sensitivity to CD99/FLT3 antibody-based nanoparticles. MV4-11 cells were selected with resistance to increasing concentrations of midostaurin during several months of culture and evaluated by flow cy…
View article: Figure 7 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 7 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Signaling pathways and genes affected by the treatment with CD99/FLT3 fusion proteins. Following incubation of MV4-11 with treatments or controls, cell lysates were assessed using western blot against common signaling pathways associated w…
View article: Figure 2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Construction and biophysical characterization of an ELP fusion protein targeting both CD99 and FLT3 receptors. A, A single-chain variable fragment targeting either CD99 receptor or FLT3 receptor was genetically fused to the amino-terminus …
View article: Figure 4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Antibody nanoworms FLT3-A192 and CD99-A192 induce apoptosis and cell death. A–D, Trypan blue staining detects a decrease in cell viability across different cell lines FLT3-ITD+/CD99+ AML cells (MV4-11, MOLM-13), FLT3−/CD99+ cells (U937), a…
View article: Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S3 – Western Blot data from USC100 following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.
View article: Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Figure S2 – FLT3 and CD99 surface level expression in primary blasts of sample USC001 and USC100.
View article: Figure 5 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia
Figure 5 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia Open
Treatment with fusion protein formulations significantly reduced leukemia burden in NSG mice. A–C, 2 × 106 MV4-11 cells were engrafted IV into NSG mice. Mice were then treated with either A192, FLT3-A192, CD99-A192, or Co-Assembled at a do…